A head-to-head comparison revealed that both semaglutide and tirzepatide reduced the composite risk of hospitalization for HF or all-cause mortality by over 40% relative to placebo, with no significant advantage of tirzepatide over semaglutide
A subsidised diabetes cohort and a private weight-management cohort may differ in diagnosis, age, comorbidity, prescriber type, affordability, refill behaviour, and discontinuation risk
Their appetite suppression effects can be risky for adolescents who need extra nourishment during puberty and older adults who might already have diminished appetites
Trends for first-time prescribing of anti-obesity medications (AOMs): First-time prescribing of AOMs was similar in the most recent month, with first-time prescribing rates in December 2023 being about the same as November 2023
The anesthetics were administered intraperitoneally 20